Comparison · NCT02081963-2f5396f8
Nebulized Amikacin vs Nebulized Normal Saline: Bacterial Clearance Rate of Sputum
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nebulized Amikacin vs Nebulized Normal Saline: Bacterial Clearance Rate of Sputum. Trial comparisons, record NCT02081963-2f5396f8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02081963-2f5396f8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.514 | 0.402 | 0.624 | wilson | |
| Risk in group 2 | 0.232 | 0.148 | 0.344 | wilson | |
| Risk difference, group 1 minus group 2 | 0.282 | 0.123 | 0.42 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.21 | 1.37 | 3.59 | log | |
| Odds ratio, group 1 over group 2 | 3.5 | 1.7 | 7.19 | log | |
| Number needed to treat, for one more participant with the outcome on Nebulized Amikacin than on Nebulized Normal Saline | 3.55 | 2.38 | 8.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nebulized Amikacin | Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.~Amikacin: Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment. | 38 | 74 | OG000 |
| Group 2 | Nebulized Normal Saline | Participants received nebulized normal saline BID for 14 days in combination with standard treatment.~Normal saline: Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment. | 16 | 69 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Bacterial Clearance Rate of Sputum
- Description
The bacterial eradication rate of the sputum was calculated by the number of P. aeruginosa-eradicated cases according to sputum culture testing result. Sputum samples were collected in the morning after toothbrushing and gargling, before the patients used any medicine. Eligible sputum samples were defined as having ≥25 white blood cells/highpower field and ≤10 epithelial cells/high-power field; the samples were sent for testing within 60 min. Sputum samples were collected again after 14 days. If the second sputum culture test showed a negative result after the first one had been positive, it was defined as eradicated.
- Time frame
- after 14 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
- NCT number
- NCT02081963
- Phases
- PHASE4
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- Amikacin, Normal saline
- Lead sponsor
- Qilu Hospital of Shandong University
- Results first posted
- 2019-04-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02081963?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02081963-2f5396f8